LIFE CHANGING EARLY DETECTION: WE WANT TO ACCELERATE IMPLEMENTATION AND MAKE LUNG CANCER SCREENING ACCESSIBLE FOR THOSE WHO BENEFIT.

ABOUT iDNA

“Life changing early detection.” Up to now medical doctors were in most instances only able to extend the lives of people diagnosed with lung cancer. This is because lung cancer is almost always diagnosed in a late stage where survival rates are very low: nine out of ten persons that are diagnosed with a stage 4 lung cancer tumour will not be alive in five years. There have been big advancements in medication and treatment in the last decades, but due to the late stage diagnosis, these advancements were mainly live-extending and not live-saving. Recently, the results of the NELSON trial were published in the New England Journal of Medicine, showing low-dose CT-scans could detect lung cancer in an early stage and thereby reduce lung cancer mortality by 24% in males in a high-risk population (for the abstract, click on the image to the right). Therefore, the institute for DiagNostic Accuracy (iDNA) wants to accelerate high quality implementation and make lung cancer screening accessible for those who benefit.

Besides lung cancer screening, we have recently also engaged in helping in the fight against the COVID-19 pandemic. Check out our news item below or the article to the far right.

FEATURED NEWS

Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study

Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study 2560 1707 iDNA

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy…

IDNA_lungscreening

Start of the 4-In-The-Lung-Run trial in the Netherlands

Start of the 4-In-The-Lung-Run trial in the Netherlands 2560 1708 iDNA

Start of the 4-In-The-Lung-Run trial in the Netherlands   We are honored to be part of the European H2020 4-In-The-Lung-Run (4ITLR) Lung Cancer Screening trial with Dutch (ErasmusMC, Dutch Cancer…

Lung_screening_IDNA

AI shows promise in significantly reducing radiologist workload

AI shows promise in significantly reducing radiologist workload 1920 1440 iDNA

New iDNA publication! iDNA and partners have published new research validating the clinical performance of AI software in the medical scientific journal Lung Cancer: “Outstanding negative prediction performance of solid…

Key Dutch publication on COVID-19 featured in Radiology special edition

Key Dutch publication on COVID-19 featured in Radiology special edition 1078 1217 iDNA

The diagnosis, prevention and treatment on COVID-19 from April 9th is now featured in Radiology’s special edition of their most highly cited and most influential articles published during the pandemic…


OUR COLLABORATIONS AND SOLUTIONS

Privacy Preferences

When you visit our website, it may store information through your browser from specific services, usually in the form of cookies. Here you can change your Privacy preferences. It is worth noting that blocking some types of cookies may impact your experience on our website and the services we are able to offer.

Click to enable/disable Google Analytics tracking code.
Click to enable/disable Google Fonts.
Click to enable/disable Google Maps.
Click to enable/disable video embeds.
Our website uses cookies to remember your preferences (e.g. the language of the website)